Thursday, 27 Feb 2020

Biologic/Novel Rx

Datesort ascending Type Title Save
20 Feb 2020 News Tofacitinib Effective in Refractory Still's Disease
19 Feb 2020 ACR Video QD Clinic - Dosing RTX and REM
17 Feb 2020 ACR Video Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD
15 Feb 2020 Social RT @RheumNow: Fenebrutinib, a BTK inhibitor, is better that placebo, but not ADA when given in a phase 2 trial. Drs. Fleischman/Genovese…
15 Feb 2020 Social RT @Janetbirdope: Do we need another IL6 inhibitor for rheumatic diseases. Tocilizumab is off patent in USA and Europe. We have Sarilumab b…
15 Feb 2020 Social Finch 3 trial in MTX naive pts shows that mono Rx FIL 200=MTX mono for ACR20 but FIL200 superior for ACR50/70. 200mg works faster with more big responders early. Drs. Fleischman/Genovese at #RWCS2020 @RWCSmtg https://t.co/msgB6DS5cl
15 Feb 2020 Social RT @HealioRheum: A novel TYK2 inhibitor may provide clinicians with another treatment option along the janus kinase pathway in patients wit…
13 Feb 2020 Social RT @Janetbirdope: Adalimumab seeems better than infliximab Behcet’s uveitis. Alvin Wells #RWCS2020 @RheumNow https://t.co/dYrKyNjASB
13 Feb 2020 Social RT @uptoTate: Biosimilars 2019 (not all yet available in the US) Drs. Cush and Kavanaugh @RheumNow @RWCSmtg #RWCS20 https://t.co/mvBj3dzQa2
10 Feb 2020 Social New Am Gastroenterology Assn Guidelines on Rx of Ulcerative colitis list infliximab, adalimumab, golimumab, vedolizumab, ustekinumab and tofacitinib for moderate to severe UC. Rec against TOFA until failing a TNFi; against using MTX. https://t.co/b0Xap3ijK7
06 Feb 2020 Social QD Clinic - Part 4 of my discussion of 2020 EULAR recommendations for RA treatment - this one addresses Adding Biologics or JAK inhibitors. Watch on Youtube https://t.co/SXcUXkceIV or Listen to the podcast https://t.co/IOjwlb9uQP
27 Jan 2020 ACR Video QD Clinic - When Would You Use Anakinra?
22 Jan 2020 News QD Clinic - Hepatitis B and Biologics
21 Jan 2020 News Biosimilars for Rheum Disease: Failure to Launch
17 Jan 2020 Social Analysis of worldwide data on Abatacept shows that compared with other bDMARDs, ABA was not associated with an increased overall cancer risk [ROR 0.98 (95% CI 0.91, 1.05)], but may be increased for risk of melanoma [1.58 (95% CI 1.17, 2.08)] https://t.co/3EI52M5kIR
02 Jan 2020 News Best of 2019 - Is Methotrexate Necessary with Tofacitinib?
01 Jan 2020 Social Do biologics work in relapsing polychondritis? French cohort of 41 pts use 105 biologics (TNFi=60; TCZ 17; anakinra 15; RTX 7; ABA6). While 63% resp in 1st 6 mos (on pred!), a complete response rate was 19%. Steroid sparing variable, high infx rates. https://t.co/knZqEAw9mb
31 Dec 2019 News Best of 2019 - Ups and Downs with Abatacept
30 Dec 2019 News Best of 2019 - Are Non-TNF Biologics Superior to TNF inhibitors?
26 Dec 2019 News Best of 2019 - New EMA Warnings for Tofacitinib in Patients at Risk for Clots